Biosensors & POCT– category –
-
Biosensors & POCT Weekly Report June 28, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report June 28, 2026 (PDF) — Download Weekly Report June 28, 2026 (PDF) — DownloadDownload 🎙 Podcast June 28, 2026 (... -
Roche Diagnostics Strengthens Comprehensive POCT Portfolio, Driving Rapid and Accurate On-Site Diagnostics for Critical Conditions
Roche Diagnostics Switzerland Overview Roche Diagnostics, in an update dated June 23, 2026, announced the strengthening of its comprehensive Point of Care (POCT) solutions portfolio. The company emphasizes the critical role of POCT in fr... -
Dexcom Advances ‘Glucose Biosensing for All’ Vision with Pediatric Clearance for Stelo Biosensor and Relaunch of Redesigned App
Business Wire USA Overview Dexcom announced key milestones at Aspen Ideas: Health, including pediatric clearance for its Stelo Glucose Biosensor and the July launch of a redesigned Stelo app for Apple and Android users. These advancement... -
IBM Unveils Sub-1 Nanometer Nanostack Chip with 100 Billion Transistors, Establishing Foundational Platform for Next-Gen Biosensors
StockNews.com USA Overview IBM has announced a sub-1 nanometer chip technology utilizing a novel Nanostack transistor architecture, capable of hosting nearly 100 billion transistors on a fingernail-sized chip. This represents a monumenta... -
Wearable Electrochemical Aptamer Sensor Achieves Ultra-Sensitive Cortisol Detection in Artificial Sweat with 93.4% Stability Over 56 Days: ACS Omega Study
ACS Omega (American Chemical Society) International Overview Research in ACS Omega reports the successful development of a long-term stable wearable DNA aptamer sensor for non-invasive cortisol sensing via sweat. Utilizing a modified scr... -
Oxford Researchers Secure ARIA Funding to Develop Transformative ‘Smart’ DNA Medicines Activating Targeted Antiviral Therapies Through Programmable Biosensors
University of Oxford UK Overview Oxford University researchers have received ARIA funding for the iGATE project, aiming to develop 'smart' DNA medicines based on programmable synthetic biosensors. These biosensors are designed to detect ... -
ADA 2026: CGM Applications Expand to Type 2 Diabetes; Continuous Ketone Monitoring and Dual Sensors Advance DKA Prevention
Pharmacy Times USA Overview The 86th American Diabetes Association (ADA) Scientific Sessions in 2026 highlighted a significant expansion of continuous glucose monitoring (CGM) beyond intensive insulin management to a broader Type 2 diabe... -
Sensor-Integrated Organ-on-Chip Devices Advance Drug Screening and Tissue Engineering with High Efficiency and Automation Capabilities
PMC (PubMed Central) International Overview A paper featured in PMC reports significant advancements in sensor-integrated organ-on-chip (OoC) devices, specifically a platform incorporating multisensory systems for drug screening and tiss... -
ASCO Annual Meeting 2026 Signals New Era in Lung Cancer Treatment: Adjuvant Targeted Therapy and ADCs Reshape Immunotherapy Strategies
Targeted Oncology USA Overview Targeted Oncology reports that three key lung cancer abstracts from the ASCO 2026 Annual Meeting could significantly alter clinical practice. These presentations highlight advances in adjuvant targeted ther... -
CNET Names Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as Top Continuous Glucose Monitors for 2026, Setting New Standards in Blood Sugar Management
CNET USA Overview CNET's 2026 review identifies Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as leading continuous glucose monitoring (CGM) devices. These systems excel in sensor life, accuracy, and FDA approval status,...
